HIV antigen incorporation within adenovirus hexon hypervariable 2 for a novel HIV vaccine approach

PLoS ONE

Volumn 5, Issue 7, 2010, Pages

  Matthews, Qiana L ^a,b   Fatima, Aiman ^a   Tang, Yizhe ^a   Perry, Brian A ^c   Tsuruta, Yuko ^a   Komarova, Svetlana ^a   Timares, Laura ^a   Zhao, Chunxia ^d   Makarova, Natalia ^d   Borovjagin, Anton V ^a   Stewart, Phoebe L ^e   Wu, Hongju ^a   Blackwell, Jerry L ^d   Curiel, David T ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c DAVIDSON COLLEGE   (United States)

^d EMORY UNIVERSITY   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CAPSID PROTEIN; EPITOPE; GAG PROTEIN; GAMMA INTERFERON; GLYCOPROTEIN GP 41; HEXON HYPERVARIABLE REGION 2; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; MEMBRANE PROXIMAL ECTODOMAIN REGION PEPTIDE; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VIRUS DNA; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; PEPTIDE;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA MODIFICATION; DRUG DESIGN; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; POLYMERASE CHAIN REACTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; SEROLOGY; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; THERMOSTABILITY; TRANSGENE; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRION; VIROGENESIS; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS RECOMBINANT; WESTERN BLOTTING; ADENOVIRUS; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMISTRY; FLOW CYTOMETRY; GENE VECTOR; GENETICS; IMMUNOLOGY; SYNTHESIS;

ADENOVIRIDAE; MIRIDAE;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; BLOTTING, WESTERN; CELL LINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENETIC VECTORS; HIV ANTIBODIES; HIV ANTIGENS; HIV ENVELOPE PROTEIN GP41; HUMANS; IMMUNITY, HUMORAL; MICE; MICE, INBRED BALB C; PEPTIDES;

EID: 77955615936     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0011815     Document Type: Article

References (59)

1. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ (2000) Development of a preventive vaccine for Ebola virus infection in primates. Nature 408: 605-9.
2. Liu RY, Wu LZ, Huang BJ, Huang JL, Zhang YL, et al. (2005) Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results inspecific humoral immune responses against SARS-CoV in rats. Virus Res 112: 24-31.
3. Gomez-Roman VR, Robert-Guroff M (2003) Adenoviruses as vectors for HIV vaccines. AIDS Rev 5: 178-85.
4. Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, et al. (2005) Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest 115: 1281-9.
5. Kay MA, Glorioso JC, Naldini L (2001) Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics. Nat Med 7: 33-40.
6. Barnett BG, Crews CJ, Douglas JT (2002) Targeted adenoviral vectors. Biochim Biophys Acta 1575: 1-14.
7. Curiel DT (1999) Strategies to adapt adenoviral vectors for targeted delivery. Ann N Y Acad Sci 886: 158-71.
8. Liu M, Acres B, Balloul JM, Bizouarne N, Paul S, et al. (2004) Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 101 Suppl 2:14567-71.
9. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, et al. (1999) Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-83.
10. Kass-Eisler A, Falck-Pedersen E, Elfenbein DH, Alvira M, Buttrick PM, et al. (1994) The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1: 395-402.
11. Kass-Eisler A, Leinwand L, Gall J, Bloom B, Falck-Pedersen E (1996) Circumventing the immune response to adenovirus-mediated gene therapy. Gene Ther 3: 154-62.
12. Wohlfart C (1988) Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms. J Virol 62: 2321-8.
13. Schagen FH, Ossevoort M, Toes RE, Hoeben RC (2004) Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion. Crit Rev Oncol Hematol 50: 51-70.
14. McConnell MJ, Danthinne X, Imperiale MJ (2006) Characterization of a permissive epitope insertion site in adenovirus hexon. J Virol 80: 5361-70.
15. Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, et al. (2004) Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses. J Virol 78: 2572-80.
16. Matthews QL, Yang P, Wu Q, Belousova N, Rivera AA, et al. (2008)Optimization of capsid-incorporated antigens for a novel adenovirus vaccine approach. Virol J 5: 98.
17. Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, et al. (2006) Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity. J Virol 80: 5523-30.
18. Crompton J, Toogood CI, Wallis N, Hay RT (1994) Expression of a foreign epitope on the surface of the adenovirus hexon. J Gen Virol 75 (Pt1): 133-9.
19. Wu H, Han T, Belousova N, Krasnykh V, Kashentseva E, et al. (2005) Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol 79: 3382-90.
20. Abe S, Okuda K, Ura T, Kondo A, Yoshida A, et al. (2009) Adenovirus type 5 with modified hexons induces robust transgene-specific immune responses in mice with pre-existing immunity against adenovirus type 5. J Gene Med 11: 570-9.
21. Worgall S, Krause A, Qiu J, Joh J, Hackett NR, et al. (2007) Protective immunity to pseudomonas aeruginosa induced with a capsid-modified adenovirus expressing P. aeruginosa OprF. J Virol 81: 13801-8.
22. Vigne E, Mahfouz I, Dedieu JF, Brie A, Perricaudet M, et al. (1999) RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 73: 5156-61.
23. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, et al. (1994) Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 10: 359-69.
24. Purtscher M, Trkola A, Grassauer A, Schulz PM, Klima A, et al. (1996) Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5. AIDS 10: 587-93.
25. Purtscher M, Trkola A, Gruber G, Buchacher A, Predl R, et al. (1994) A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 10: 1651-8.
26. Wu H, Dmitriev I, Kashentseva E, Seki T, Wang M, et al. (2002) Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol 76: 12775-82.
27. Zhao C, Crews CJ, Derdeyn CA, Blackwell JL (2009) Lac-regulated system for generating adenovirus 5 vaccine vectors expressing cytolytic human immunodeficiency virus 1 genes. J Virol Methods 160: 101-10.
28. Wu H, Seki T, Dmitriev I, Uil T, Kashentseva E, et al. (2002) Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther 13: 1647-53.
29. Zhang HG, High KA, Wu Q, Yang P, Schlachterman A, et al. (2005) Genetic analysis of the antibody response to AAV2 and factor IX. Mol Ther 11: 866-74.
30. Dmitriev IP, Kashentseva EA, Curiel DT (2002) Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol 76: 6893-9.
31. Tang Y, Le LP, Matthews QL, Han T, Wu H, et al. (2008) Derivation of a triple mosaic adenovirus based on modification of the minor capsid protein IX. Virology 377: 391-400.
32. Ofek G, Tang M, Sambor A, Katinger H, Mascola JR, et al. (2004) Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 78: 10724-37.
33. Chan DC, Kim PS (1998) HIV entry and its inhibition. Cell 93: 681-4.
34. Spearman P, Wang JJ, Vander HN, Ratner L (1994) Identification of human immunodeficiency virus type 1 Gag protein domains essential to membrane binding and particle assembly. J Virol 68: 3232-42.
35. Li J, Le L, Sibley DA, Mathis JM, Curiel DT (2005) Genetic incorporation of HSV-1 thymidine kinase into the adenovirus protein IX for functional display on the virion. Virology 338: 247-58.
36. Jerry LB, Hui L, Jesus G, Igor D, Victor K, et al. (2000) Using a Tropism-Modified Adenoviral Vector to Circumvent Inhibitory Factors in Ascites Fluid. Human Gene Therapy 11: 1657-69.
37. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, et al. (2005) Structure of a V3-containing HIV-1 gp120 core. Science 310: 1025-8.
38. Challacombe SJ, Naglik JR (2006) The effects of HIV infection on oral mucosalimmunity. Adv Dent Res 19: 29-35.
39. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, et al. (2004) Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2-exposed IgG-seronegative individuals. J Virol 78: 7016-22.
40. Mestecky J (2007) Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 73: 86-97.
41. Sekaly RP (2008) The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 205: 7-12.
42. Nabel GJ (2001) Challenges and opportunities for development of an AIDS vaccine. Nature 410: 1002-7.
43. Barouch DH, Nabel GJ (2005) Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16: 149-56.
44. Smith AD, Geisler SC, Chen AA, Resnick DA, Roy BM, et al. (1998) Human rhinovirus type 14:human immunodeficiency virus type 1 (HIV-1) V3 loop chimeras from a combinatorial library induce potent neutralizing antibody responses against HIV-1. J Virol 72: 651-9.
45. Arnold GF, Velasco PK, Holmes AK, Wrin T, Geisler SC, et al. (2009) Broad neutralization of human immunodeficiency virus type 1 (HIV-1) elicited from human rhinoviruses that display the HIV-1 gp41 ELDKWA epitope. J Virol 83: 5087-100.
46. Resnick DA, Smith AD, Gesiler SC, Zhang A, Arnold E, et al. (1995) Chimeras from a human rhinovirus 14-human immunodeficiency virus type 1 (HIV-1) V3 loop seroprevalence library induce neutralizing responses against HIV-1. J Virol 69: 2406-11.
47. Zhang A, Geisler SC, Smith AD, Resnick DA, Li ML, et al. (1999) A disulfidebound HIV-1 V3 loop sequence on the surface of human rhinovirus 14 induces neutralizing responses against HIV-1. Biol Chem 380: 365-74.
48. Smith AD, Resnick DA, Zhang A, Geisler SC, Arnold E, et al. (1994) Use of random systematic mutagenesis to generate viable human rhinovirus 14 chimeras displaying human immunodeficiency virus type 1 V3 loop sequences. J Virol 68: 575-9.
49. Arnold GF, Resnick DA, Smith AD, Geisler SC, Holmes AK, et al. (1996) Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology 39: 72-8.
50. Noureddini SC, Krendelshchikov A, Simonenko V, Hedley SJ, Douglas JT, et al. (2006) Generation and selection of targeted adenoviruses embodying optimized vector properties. Virus Res 116: 185-95.
51. Pereboev A, Pereboeva L, Curiel DT (2001) Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J Virol 75: 7107-13.
52. Douglas JT, Miller CR, Kim M, Dmitriev I, Mikheeva G, et al. (1999) A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat Biotechnol 17: 470-5.
53. Umana P, Gerdes CA, Stone D, Davis JR, Ward D, et al. (2001) Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol 19: 582-5.
54. Lowenstein PR, Thomas CE, Umana P, Gerdes CA, Verakis T, et al. (2002) High-capacity, helper-dependent, ''gutless'' adenoviral vectors for gene transfer into brain. Methods Enzymol 346: 292-311.
55. Xiong W, Goverdhana S, Sciascia SA, Candolfi M, Zirger JM, et al. (2006) Regulatable gutless adenovirus vectors sustain inducible transgene expression in the brain in the presence of an immune response against adenoviruses. J Virol 80: 27-37.
56. Xiong W, Candolfi M, Kroeger KM, Puntel M, Mondkar S, et al. (2008) Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain. Mol Ther 16: 343-51.
57. Weaver EA, Nehete PN, Buchl SS, Senac JS, Palmer D, et al. (2009) Comparison of replication-competent, first generation, and helper-dependent adenoviral vaccines. PLoS One 4: e5059.
58. Weaver EA, Barry MA (2008) Effects of Shielding Adenoviral Vectors with Polyethylene Glycol (PEG) on Vector-specific and Vaccine-mediated Immune Responses. Hum Gene Ther.
59. Thacker EE, Timares L, Matthews QL (2009) Strategies to overcome host immunity to adenovirus vectors in vaccine development. Expert Rev Vaccines 8: 761-77.